British Society for Haematology (BSH) 2021
C3 Inhibition With Pegcetacoplan In Patients With Paroxysmal Nocturnal Hemoglobinuria: Results From The Paddock And Palomino Trials
Categorized Hematologic Response To Pegcetacoplan Versus Eculizumab In Patients With Paroxysmal Nocturnal Hemoglobinuria: Post Hoc Analysis Of Data From A Phase 3 Randomized Trial (PEGASUS)
Comparative Effectiveness Of Pegcetacoplan Versus Ravulizumab In Patients With Paroxysmal Nocturnal Hemoglobinuria Previously Treated With Eculizumab: A Matching-Adjusted Indirect Comparison
Effect Of Pegcetacoplan On Quality Of Life In Patients With Paroxysmal Nocturnal Hemoglobinuria From The Pegasus Phase 3 Trial Comparing Pegcetacoplan To Eculizumab
Improvements In Fatigue And Physical Function Evaluated Through Changes In Clinical Outcomes In Paroxysmal Nocturnal Hemoglobinuria: Post-Hoc Analyses From The PEGASUS Study
Injection-Site Reactions In The Randomized Phase 3 PEGASUS Trial Of Pegcetacoplan Compared With Eculizumab For Individuals With Paroxysmal Nocturnal Hemoglobinuria
Results Of The Pegasus Phase 3 Randomized Trial Demonstrating Superiority Of The C3 Inhibitor, Pegcetacoplan, Compared To Eculizumab In Patients With Paroxysmal Nocturnal Hemoglobinuria
Superiority Of Pegcetacoplan Compared To Eculizumab In Patients With Paroxysmal Nocturnal Hemoglobinuria, Regardless Of Prior Transfusion Requirement: Analysis At 16-Weeks Of PEGASUS Phase 3 Randomized Trial